TABLE 1.
The basic information of miRNA in ferroptosis signaling pathway.
| miRNA | Research object | Target | Progress on ferroptosis | References |
|---|---|---|---|---|
| miR-545 | Colorectal cancer | TF | Inhibition | Zheng et al. (2021) |
| miR-19a | Colorectal cancer | IREB2 | Inhibition | Fan et al. (2022) |
| miR-4735-3p | Clear cell renal cell carcinoma | FPN | Promotion | Zhu et al. (2022) |
| miR-129-5p | Bladder cancer | PROM2 | Promotion | Luo W. et al. (2021) |
| miR-19b-3p | Lung cancer | FTH1 | Inhibition | Zhang R. et al. (2022) |
| miR-375 | Gastric cancer | SLC7A11 | Promotion | Ni et al. (2021) |
| miR-5096 | Breast cancer | SLC7A11 | Promotion | Yadav et al. (2021) |
| miR-382-5p | Ovarian and breast cancer | SLC7A11 | Promotion | Sun D. et al. (2021) |
| miR-489-5p | Gastric cancer | SLC7A11 | Promotion | Mao et al. (2021) |
| miR-545-3p | Thyroid cancer | SLC7A11 | Promotion | Wang H.H. et al. (2021) |
| miR-125b-5p | Oral squamous cell carcinomas | SLC7A11 | Promotion | Yu et al. (2021) |
| miR-34c-3p | Oral squamous cell carcinomas | SLC7A11 | Promotion | Sun et al. (2022) |
| miR-375-3p | Cervical cancer | SLC7A11 | Promotion | Wu et al. (2021) |
| miR-409-3p | Cervical cancer | SLC7A11 | Promotion | Wu et al. (2021) |
| miR-515-5p | Cervical cancer | SLC7A11 | Promotion | Wu et al. (2021) |
| miR-1261 | Hepatocellular carcinoma | SLC7A11 | Promotion | Lyu et al. (2021) |
| miR-25-3p | Prostate cancer | SLC7A11 | Promotion | Jiang et al. (2022) |
| miR-143-3p | Renal cell carcinoma | SLC7A11 | Promotion | Li et al. (2022) |
| miR-15a-3p | Colorectal cancer | GPX4 | Promotion | Liu et al. (2022) |
| miR-539 | Colorectal cancer | GPX4 | Promotion | Yang Y. et al. (2021) |
| miR-324-3p | Lung adenocarcinoma | GPX4 | Promotion | Deng et al. (2021) |
| miR-324-3p | Breast cancer | GPX4 | Promotion | Hou et al. (2021) |
| miR-214-3p | Liver cancer | GPX4 | Promotion | He et al. (2021) |
| miR-1287-5p | Osteosarcoma | GPX4 | Promotion | Xu Z. et al. (2021) |
| miR-1231 | Papillary thyroid cancer | GPX4 | Promotion | Chen W.et al. (2021) |
| miR-15a | Prostate cancer | GPX4 | Promotion | Xu et al. (2022) |
| miR-541-3p | Hepatocellular carcinoma | GPX4 | Promotion | Xu et al. (2020) |
| miR-1287-5p | Non-small cell lung cancer | GPX4 | Promotion | Shanshan et al. (2021) |
| miR-522 | Gastric cancer | ALOX15 | Inhibition | Zhang et al. (2020) |
| miR-7-5p | Radioresistant HeLa and SAS cell lines | ALOX12 | Inhibition | Tomita et al. (2021) |
| miR-18a | Glioblastoma | ALOXE3 | Inhibition | Yang X. et al. (2021) |
| miR-23a-3p | Hepatocellular carcinoma | ACSL4 | Inhibition | Lu Y. et al. (2022) |
| miR-424-5p | Ovarian cancer | ACSL4 | Inhibition | Ma et al. (2021) |
| miR-670-3p | Glioblastoma | ACSL4 | Inhibition | Bao et al. (2021) |
| miR-4291 | Cervical cancer | ACSL4 | Inhibition | Ou et al. (2022) |
| miR-4443 | Non-small cell lung carcinoma | FSP1 | Inhibition | Song et al. (2021) |
| miR-1228 | HER-2-positive breast cancer | FSP1 | Inhibition | Bazhabayi et al. (2021) |
| miR-6077 | Lung adenocarcinoma | NRF2 | Promotion | Bi et al. (2022) |
| miR-450b-5p | Nasopharyngeal carcinoma | NRF2 | Promotion | Huang et al. (2020) |
| miR-130b-3p | Melanoma | NRF2 | Inhibition | Liao et al. (2021) |
| miR-365a-3p | Non-small cell lung cancer | NRF2 | Promotion | Gai et al. (2020) |
| miR-137 | Melanoma | SLC1A5 | Inhibition | Luo et al. (2018) |
| miR-9 | Melanoma | GOT1 | Inhibition | Zhang et al. (2018a) |
| miR-214-5p | Hepatoma | ATF4 | Promotion | Bai et al. (2020) |
| miR-3200-5p | Hepatocellular carcinoma | ATF4 | Promotion | Guan et al. (2022) |
| miR-106a-5p | Breast cancer | STAT3 | Promotion | Zhang et al. (2021a) |
| miR-125b-5p | Gastric cancer | STAT3 | Promotion | Liu Y.P. et al. (2021) |
| miR-27a-3p | Esophageal cancer | GCH1 | Promotion | Lu M. et al. (2022) |
| miR-101-3p | Lung cancer | TBLR1 | Promotion | Luo Y. et al. (2021) |
| miR-21-3p | Melanoma | TXNRD1 | Promotion | Luo Y. et al. (2021) |
This table collates the relationship between miRNAs and ferroptosis targets in different tumors and their promoting or inhibiting effects on ferroptosis process.
TF, Transferrin; IREB2, Iron response element binding protein 2; FPN, ferroportin; PROM2, Prominin2; FTH1, Ferritin heavy chain 1; SLC7A11, Solute carrier family member 7A11; GPX4, Glutathione peroxidase 4; ALOX15, Arachidonic acid lipid peroxidase 15; ALOX12, Arachidonic acid lipid peroxidase 12; ALOXE3, Arachidonic acid lipid peroxidase E3; ACSL4, Long chain acyl CoA synthetase 4; FSP1, ferroptosis suppressor protein 1; NRF2, Nuclear factor E2 related factor 2; SLC1A5, Glutamine transporter; GOT1, Glutamic-oxaloacetic transaminase 1; ATF4, Activating transcription factor 4; STAT3, Signal transducer and activator of transcription 3; GCH1, GTP cyclohydrolase 1; TBLR1, Transducin beta 1X-linked receptor protein 1; TXNRD1, Thioredoxin reductase 1.